Table 2.

Changes in dd-cfDNA post-biopsy by type of rejection

Group	1-Month Follow-up				2–3-Month Follow-up
	N	Month 0, Median (25th, 75th), %	Month 1, Median (25th, 75th), %	P	N	Month 0, Median (25th, 75th), %	Month 2–3, Median (25th, 75th), %	P
BPAR or treated rejection	21	0.62 (0.26, 1.23)	0.35 (0.23, 0.96)	0.34	23	0.77 (0.23, 2.91)	0.21 (0.11, 0.63)	0.002
Clinical (no BPAR)	10	0.31 (0.25, 0.60)	0.29 (0.22, 0.41)	0.38	8	0.38 (0.23, 1.26)	0.17 (0.14, 0.26)	0.31
ABMR	6	1.61 (1.02, 3.28)	1.20 (0.50, 4.94)	>0.99	6	3.85 (2.54, 6.10)	1.32 (0.42, 3.87)	0.09
TCMR	5	1.13 (0.26, 1.23)	0.37 (0.31, 1.35)	0.63	9	0.25 (0.21, 0.77)	0.12 (0.06, 0.23)	0.004
No BPAR or treated rejection	21	0.23 (0.11, 0.41)	0.18 (0.08, 0.24)	0.10	26	0.33 (0.12, 0.57)	0.17 (0.06, 0.28)	0.003
Control	36	0.37 (0.21, 0.51)	0.25 (0.17, 0.52)	0.27	62	0.24 (0.12, 0.42)	0.15 (0.08, 0.23)	0.004

The study groups are listed in the first column. For each group, distribution of dd-cfDNA at time of biopsy, at first test at 1 mo, and after 2–3 mo is given, along with the number of patients in each group with a dd-cfDNA measurement at that time point. Finally, a P value is given, showing whether dd-cfDNA exhibits a statistically significant change from time of biopsy to follow-up time for two different follow-up times: at 1 mo and at 2–3 mo. dd-cfDNA, donor-derived cell-free DNA; BPAR, biopsy–proven acute rejection; ABMR, antibody-mediated rejection; TCMR, T cell–mediated rejection.